Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Osimertinib Resistance Analysis in Patients With EGFR Mutation Positive Non-small-cell Lung Carcinoma That Have Progressed on Osimertinib Treatment'

NCT04737382 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT04737382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04737382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Osimertinib Resistance Analysis in Patients With EGFR Mutation Positive Non-small-cell Lung Carcinoma That Have Progressed on Osimertinib Treatment'
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Unknown status
Start date
August 22, 2019
Completion date
August 22, 2024
Enrollment
200 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma